Bicycle Therapeutics (BCYC) News Today $8.05 -0.46 (-5.41%) Closing price 04:00 PM EasternExtended Trading$8.04 -0.02 (-0.19%) As of 05:08 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock BCYC Latest News All Sources Trusted Sources MarketBeat Benzinga Bloomberg GlobeNewswire GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent May 2025 April 2025 March 2025 February 2025 January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 Time Period Bicycle Therapeutics plc (NASDAQ:BCYC) Stock Position Trimmed by Tybourne Capital Management HK Ltd.Tybourne Capital Management HK Ltd. lessened its stake in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 9.0% during the 4th quarter, according to its most recent 13F filing with the SEC. The firm owned 1,269,535 shares of the company's stock after selling 125,000 shares during tMay 21 at 6:46 AM | marketbeat.comPoint72 Asset Management L.P. Acquires 3,655,101 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC)Point72 Asset Management L.P. boosted its position in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 406.2% during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 4,554,900 shares of the company'sMay 18 at 6:14 AM | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) Receives $25.00 Average Target Price from BrokeragesMay 18 at 1:31 AM | americanbankingnews.comBicycle Therapeutics plc (NASDAQ:BCYC) Given Average Rating of "Moderate Buy" by AnalystsBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) has earned a consensus recommendation of "Moderate Buy" from the ten analysts that are presently covering the firm, Marketbeat Ratings reports. Three equities research analysts have rated the stock with a hold recommendation and seven have giMay 17, 2025 | marketbeat.comParkman Healthcare Partners LLC Sells 92,915 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC)Parkman Healthcare Partners LLC decreased its holdings in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 20.9% in the 4th quarter, according to its most recent Form 13F filing with the SEC. The firm owned 352,481 shares of the company's stock after selling 92,915 shares during thMay 16, 2025 | marketbeat.comCantor Fitzgerald Issues Negative Estimate for BCYC EarningsMay 13, 2025 | americanbankingnews.comBCYC FY2025 EPS Estimate Lowered by Cantor FitzgeraldBicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Cantor Fitzgerald lowered their FY2025 earnings estimates for shares of Bicycle Therapeutics in a report issued on Thursday, May 8th. Cantor Fitzgerald analyst L. Watsek now anticipates that the company will earn ($3.87) per share for the yeaMay 13, 2025 | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) Stock Position Decreased by Schonfeld Strategic Advisors LLCSchonfeld Strategic Advisors LLC decreased its position in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 90.0% in the 4th quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 42,500 shares of the company's stock after selling 380,May 12, 2025 | marketbeat.comFcpm Iii Services B.V. Has $48.33 Million Stock Position in Bicycle Therapeutics plc (NASDAQ:BCYC)Fcpm Iii Services B.V. raised its stake in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 47.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 3,452,330 shares of the companyMay 11, 2025 | marketbeat.comVoya Investment Management LLC Lowers Position in Bicycle Therapeutics plc (NASDAQ:BCYC)Voya Investment Management LLC decreased its stake in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 54.0% in the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor owned 48,420 shares of thMay 11, 2025 | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) Shares Sold by Deep Track Capital LPDeep Track Capital LP cut its stake in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 64.0% in the fourth quarter, according to its most recent disclosure with the SEC. The firm owned 1,276,081 shares of the company's stock after selling 2,271,920 shares during the period. Deep TMay 9, 2025 | marketbeat.comCaption Management LLC Purchases New Position in Bicycle Therapeutics plc (NASDAQ:BCYC)Caption Management LLC acquired a new stake in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) during the fourth quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The fund acquired 163,076 shares of the company's stock, valMay 9, 2025 | marketbeat.comWhat is HC Wainwright's Estimate for BCYC FY2029 Earnings?Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) - Research analysts at HC Wainwright raised their FY2029 earnings estimates for Bicycle Therapeutics in a report released on Thursday, May 1st. HC Wainwright analyst S. Ramakanth now anticipates that the company will post earnings of $1.22 perMay 7, 2025 | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) Stock Position Increased by Baker BROS. Advisors LPBaker BROS. Advisors LP grew its position in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 15.8% in the 4th quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 10,885,357 shares of the company's stock after purchasing anMay 6, 2025 | marketbeat.comBicycle Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)May 5, 2025 | businesswire.comBicycle Therapeutics (NASDAQ:BCYC) Posts Earnings Results, Misses Expectations By $0.02 EPSBicycle Therapeutics (NASDAQ:BCYC - Get Free Report) released its quarterly earnings data on Thursday. The company reported ($0.88) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.02). Bicycle Therapeutics had a negative net margin of 450.64% and a negative return on equity of 27.35%. The company had revenue of $9.98 million during the quarter, compared to analyst estimates of $8.67 million.May 5, 2025 | marketbeat.comIs Bicycle Therapeutics plc (BCYC) the Best Small Cap Stock to Buy with the Biggest Upside Potential?May 5, 2025 | insidermonkey.comA Glimpse Into The Expert Outlook On Bicycle Therapeutics Through 7 AnalystsMay 4, 2025 | nasdaq.comBicycle Therapeutics (NASDAQ:BCYC) Price Target Cut to $22.00 by Analysts at JMP SecuritiesJMP Securities reduced their price objective on Bicycle Therapeutics from $26.00 to $22.00 and set a "market outperform" rating on the stock in a report on Friday.May 4, 2025 | marketbeat.comBicycle Therapeutics' (BCYC) Buy Rating Reaffirmed at Needham & Company LLCNeedham & Company LLC reissued a "buy" rating and issued a $29.00 price target on shares of Bicycle Therapeutics in a research report on Friday.May 4, 2025 | marketbeat.comPrice T Rowe Associates Inc. MD Sells 136,913 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC)Price T Rowe Associates Inc. MD reduced its position in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 8.0% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 1,585,127 shares of the company's stock after sellingMay 4, 2025 | marketbeat.comB.Riley Financial Sticks to Their Hold Rating for Bicycle Therapeutics (BCYC)May 4, 2025 | theglobeandmail.comRA Capital Management L.P. Sells 1,159,523 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC)RA Capital Management L.P. lessened its position in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 51.5% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The firm owned 1,093,477 shares of the company's stock after sellinMay 3, 2025 | marketbeat.comBarclays Sticks to Its Buy Rating for Bicycle Therapeutics (BCYC)May 3, 2025 | theglobeandmail.comBicycle Therapeutics plc (NASDAQ:BCYC) Sees Significant Decline in Short InterestBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) was the recipient of a significant decline in short interest during the month of April. As of April 15th, there was short interest totalling 3,130,000 shares, a decline of 27.2% from the March 31st total of 4,300,000 shares. Currently, 5.0% of the company's stock are short sold. Based on an average daily volume of 349,300 shares, the days-to-cover ratio is currently 9.0 days.May 3, 2025 | marketbeat.comBicycle Therapeutics price target lowered to $15 from $40 at BarclaysMay 2, 2025 | finance.yahoo.comBicycle Therapeutics Announces Presentation of Additional Human Radiopharmaceutical Imaging Data for MT1-MMP at the American Association for Cancer Research Annual Meeting 2025May 1, 2025 | seekingalpha.comBicycle Therapeutics Reports Recent Business Progress and First Quarter 2025 Financial ResultsMay 1, 2025 | finance.yahoo.comLegal & General Group Plc Has $1.95 Million Stake in Bicycle Therapeutics plc (NASDAQ:BCYC)Legal & General Group Plc trimmed its position in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 41.8% in the fourth quarter, according to its most recent filing with the SEC. The fund owned 139,075 shares of the company's stock after selling 99,741 shares during the period. Legal & GeneraApril 27, 2025 | marketbeat.comBicycle Therapeutics (BCYC) to Release Quarterly Earnings on ThursdayBicycle Therapeutics (NASDAQ:BCYC) will be releasing its Q1 2025 earnings before the market opens on Thursday, May 1. (View Earnings Report at https://www.marketbeat.com/earnings/reports/2025-5-1-bicycle-therapeutics-plc-stock/)April 26, 2025 | marketbeat.comLong Focus Capital Management LLC Takes Position in Bicycle Therapeutics plc (NASDAQ:BCYC)Long Focus Capital Management LLC bought a new position in shares of Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) in the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor bought 543,092 shares of thApril 25, 2025 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Stock Price Up 9.3% - Time to Buy?Bicycle Therapeutics (NASDAQ:BCYC) Stock Price Up 9.3% - Here's WhyApril 24, 2025 | marketbeat.comBicycle Therapeutics: Maybe Underwhelming, But I Don't Think They Should Be This DiscountedApril 22, 2025 | seekingalpha.comNan Fung Group Holdings Ltd Acquires 37,358 Shares of Bicycle Therapeutics plc (NASDAQ:BCYC)Nan Fung Group Holdings Ltd raised its stake in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 118.3% in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 68,943 shares of the company's stock after acquirApril 21, 2025 | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) Receives Consensus Rating of "Moderate Buy" from BrokeragesBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) has been assigned an average recommendation of "Moderate Buy" from the eight analysts that are covering the stock, MarketBeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and six have assigned a buyApril 21, 2025 | marketbeat.comAltium Capital Management LLC Cuts Position in Bicycle Therapeutics plc (NASDAQ:BCYC)Altium Capital Management LLC lessened its position in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) by 52.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund owned 40,352 shares of the company's stApril 20, 2025 | marketbeat.comBicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up - Still a Buy?Bicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up - Here's WhyApril 17, 2025 | marketbeat.comBicycle Therapeutics' (BCYC) "Buy" Rating Reiterated at Needham & Company LLCNeedham & Company LLC restated a "buy" rating and issued a $30.00 price target on shares of Bicycle Therapeutics in a report on Wednesday.April 11, 2025 | marketbeat.com1BCYC : Analyst Expectations For Bicycle Therapeutics's FutureApril 9, 2025 | benzinga.comSpringhill Fund Asset Management HK Co Ltd Takes $1.63 Million Position in Bicycle Therapeutics plc (NASDAQ:BCYC)Springhill Fund Asset Management HK Co Ltd purchased a new position in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) during the fourth quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm purchased 116,400 shares of the cApril 8, 2025 | marketbeat.comInsider Selling: Bicycle Therapeutics plc (NASDAQ:BCYC) CEO Sells 2,237 Shares of StockBicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) CEO Kevin Lee sold 2,237 shares of the firm's stock in a transaction dated Wednesday, April 2nd. The stock was sold at an average price of $8.02, for a total value of $17,940.74. Following the sale, the chief executive officer now directly owns 489,697 shares in the company, valued at $3,927,369.94. This trade represents a 0.45 % decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through this link.April 6, 2025 | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) CEO Sells $17,940.74 in StockApril 5, 2025 | insidertrades.comBicycle Therapeutics to Participate in the 24th Annual Needham Virtual Healthcare ConferenceApril 1, 2025 | finance.yahoo.comBicycle Therapeutics (NASDAQ:BCYC) Sets New 12-Month Low - Should You Sell?Bicycle Therapeutics (NASDAQ:BCYC) Sets New 1-Year Low - Time to Sell?April 1, 2025 | marketbeat.comBicycle Therapeutics plc: Bicycle Therapeutics Announces New Board and Key Clinical Leadership AppointmentsMarch 29, 2025 | finanznachrichten.deBicycle names Pierre Legault chairman, Eric Westin chief medical officerMarch 29, 2025 | markets.businessinsider.comBicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up - Here's WhyBicycle Therapeutics (NASDAQ:BCYC) Shares Gap Up - Time to Buy?March 28, 2025 | marketbeat.comBicycle Therapeutics Announces New Board and Key Clinical Leadership AppointmentsMarch 27, 2025 | finance.yahoo.comEntryPoint Capital LLC Invests $614,000 in Bicycle Therapeutics plc (NASDAQ:BCYC)EntryPoint Capital LLC bought a new stake in Bicycle Therapeutics plc (NASDAQ:BCYC - Free Report) during the 4th quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund bought 43,873 shares of the company's stock, valued at approximately $March 26, 2025 | marketbeat.comBicycle Therapeutics plc (NASDAQ:BCYC) Receives Average Rating of "Moderate Buy" from BrokeragesShares of Bicycle Therapeutics plc (NASDAQ:BCYC - Get Free Report) have been assigned an average rating of "Moderate Buy" from the eight ratings firms that are currently covering the firm, Marketbeat reports. Two equities research analysts have rated the stock with a hold rating and six have assignMarch 26, 2025 | marketbeat.com Get Bicycle Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Email Address BCYC Media Mentions By Week BCYC Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. BCYC News Sentiment▼0.820.66▲Average Medical News Sentiment BCYC News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. BCYC Articles This Week▼55▲BCYC Articles Average Week Get Bicycle Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for BCYC and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Xenon Pharmaceuticals News Today Amneal Pharmaceuticals News Today HUTCHMED News Today Organon & Co. News Today Mirum Pharmaceuticals News Today Apellis Pharmaceuticals News Today Arrowhead Pharmaceuticals News Today Vericel News Today NewAmsterdam Pharma News Today Ascentage Pharma Group International News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:BCYC) was last updated on 5/21/2025 by MarketBeat.com Staff From Our PartnersMarket Panic: Trump Just Dropped a Bomb on Your Stockstock Market Panic: Trump Just Dropped a Bomb on Your Stocks The market is in freefall—and Trump's new tarif...American Alternative | SponsoredGold Hits New Highs as Global Markets SpiralWhen Trump took office in 2017, gold was just $1,100 an ounce. By the time he left, it had soared to $1,839. ...Premier Gold Co | SponsoredWhite House to reset Social Security?Elon Musk's parting DOGE gift looks set to shock America... A single announcement by July 22nd could soon b...Altimetry | SponsoredThe Trump Dump is starting; Get out of stocks now?The first 365 days of the Trump presidency… Will be the best time to get rich in American history.Paradigm Press | SponsoredTrump’s treachery Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to ...Porter & Company | SponsoredBuffett’s favorite chart just hit 209% – here’s what that means for goldA Historic Gold Announcement Is About to Rock Wall Street For months, sharp-eyed analysts have watched the ...Golden Portfolio | SponsoredEveryone’s watching Nvidia right now. Here’s why I’m excited.So, unless you’ve been living under a rock, you probably saw the news… Nvidia just signed a $7 BILLION deal...Timothy Sykes | SponsoredIs President Trump Lying To You With This?President Trump’s economic transition isn’t without hardship. But what if there were a smart, tax-free way to ...Colonial Metals | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Bicycle Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Bicycle Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy BCYC Stock Free BCYC Stock Alerts